| Literature DB >> 31315613 |
Xiaoyou Su1, Jing Xu1, Chao Zheng2.
Abstract
BACKGROUND: Sarcopenic obesity, central obesity combined with decreased skeletal muscle mass, is identified to be associated with metabolic syndrome and cardiovascular diseases; however, its role in the occurrence of non-alcoholic fatty liver disease (NAFLD) among patients with type 2 diabetes mellitus (T2DM) remains unclear. Therefore, this study aimed to investigate the value of the skeletal-to-visceral ratio (SVR) in the prediction of NAFLD in T2DM.Entities:
Keywords: Non-alcoholic fatty liver; Skeletal muscle mass; Skeletal muscle mass to visceral fat area ratio; Type 2 diabetes; Visceral fat area
Year: 2019 PMID: 31315613 PMCID: PMC6637487 DOI: 10.1186/s12902-019-0404-1
Source DB: PubMed Journal: BMC Endocr Disord ISSN: 1472-6823 Impact factor: 2.763
Baseline characteristics of type 2 diabetic patients with or without NAFLD
| Men | Women | |||||
|---|---|---|---|---|---|---|
| NAFLD(−) | NAFLD(+) | P | NAFLD(−) | NAFLD(+) | P | |
| N | 147 | 89 | – | 113 | 96 | – |
| Age, years | 57.6 ± 9.4 | 59.4 ± 9.8 | 0.169 | 61.1 ± 9.3 | 61.4 ± 8.7 | 0.834 |
| Duration of diabetes, years | 8.0 ± 7.1 | 6.1 ± 6.1 | 0.040 | 9.1 ± 6.6 | 7.7 ± 6.7 | 0.143 |
| Duration of hypertension, years | 3.1 ± 5.6 | 5.5 ± 7.1 | 0.05 | 5.0 ± 6.7 | 6.9 ± 7.0 | 0.045 |
| Height, cm | 167.9 ± 5.7 | 167.5 ± 5.1 | 0.596 | 154.9 ± 5.7 | 155.9 ± 5.7 | 0.201 |
| Weight, cm | 65.0 ± 9.1 | 73.6 ± 10.2 | < 0.001 | 58.3 ± 9.1 | 63.3 ± 11.7 | 0.001 |
| Body mass index, Kg/m2 | 23.0 ± 2.9 | 26.2 ± 3.4 | < 0.01 | 24.3 ± 3.5 | 26.0 ± 4.4 | 0.002 |
| Waist circumference, cm | 85.6 ± 8.5 | 94.7 ± 8.4 | < 0.001 | 86.8 ± 11.8 | 92.2 ± 11.4 | 0.001 |
| Systolic blood pressure, mmHg | 133.2 ± 21.8 | 138.4 ± 20.6 | 0.069 | 145.7 ± 26.4 | 140.8 ± 19.3 | 0.133 |
| Diastolic blood pressure, mmHg | 76.0 ± 12.5 | 80.7 ± 12.4 | 0.005 | 75.7 ± 12.8 | 76.8 ± 12.6 | 0.529 |
| Hemoglobin A1c, mmol/L | 10.3 ± 2.8 | 9.6 ± 2.2 | 0.005 | 9.4 ± 2.0 | 9.4 ± 2.1 | 0.901 |
| Total cholesterol, mmol/L | 4.2 ± 1.1 | 4.6 ± 1.3 | 0.016 | 4.6 ± 1.4 | 4.9 ± 1.4 | 0.050 |
| Triglycerides, mmol/L | 1.4 ± 0.9 | 2.3 ± 2.2 | < 0.001 | 1.9 ± 2.1 | 2.3 ± 1.8 | 0.155 |
| HDL-cholesterol, mmol/L | 1.0 ± 0.3 | 0.9 ± 0.2 | 0.152 | 1.1 ± 0.3 | 1.0 ± 0.2 | 0.390 |
| LDL-cholesterol, mmol/L | 2.5 ± 0.9 | 2.6 ± 1.0 | 0.201 | 2.6 ± 0.9 | 2.8 ± 0.9 | 0.061 |
| ALT, IU/L | 24.2 ± 14.5 | 28.5 ± 18.2 | 0.047 | 20.8 ± 11.8 | 25.0 ± 14.0 | 0.039 |
| AST, IU/L | 22.6 ± 10.5 | 25.4 ± 11.5 | 0.054 | 22.1 ± 9.7 | 25.0 ± 11.2 | 0.049 |
| Current smoking, % | 44.2 | 43.8 | 1.000 | 1.8 | 0 | 0.501 |
| Current drinking, % | 10.2 | 11.2 | 0.829 | 0 | 0 | 1.000 |
| Menopause, % | – | – | – | 89.2 | 91.3 | 0.645 |
| Medications | ||||||
| Statin (%) | 8.2 | 11.1 | 0.717 | 10.4 | 8.3 | 1.000 |
| Metformin (%) | 53.1 | 61.1 | 0.512 | 50.0 | 61.1 | 0.378 |
| Insulin (%) | 65.3 | 50.0 | 0.185 | 70.8 | 63.9 | 0.637 |
| ASM, kg | 21.5 ± 2.8 | 22.6 ± 2.7 | 0.002 | 15.4 ± 2.4 | 15.7 ± 2.6 | 0.369 |
| Visceral fat area, cm2 | 95.7 ± 25.6 | 120.7 ± 36.0 | < 0.001 | 104.7 ± 32.9 | 121.0 ± 28.8 | < 0.001 |
| SVR, g/cm2 | 238.7 ± 73.3 | 197.8 ± 57.4 | < 0.001 | 160.0 ± 58.0 | 136.7 ± 38.1 | 0.001 |
Correlation analysis between SVR levels and other variables
| Men | women | |||
|---|---|---|---|---|
| r | r | |||
| Age | −0.377 | < 0.001 | −0.332 | < 0.001 |
| Body mass index | −0.244 | < 0.001 | −0.270 | < 0.001 |
| Waist circumference | −0.309 | < 0.001 | −0.328 | < 0.001 |
| SBP | −0.179 | < 0.001 | −0.053 | 0.255 |
| DBP | − 0.057 | 0.195 | − 0.070 | 0.136 |
| Glycosylated hemoglobin A1c | 0.073 | 0.103 | −0.033 | 0.491 |
| Total cholesterol | −0.022 | 0.613 | −0.089 | 0.059 |
| Triglycerides | 0.062 | 0.159 | −0.038 | 0.412 |
| HDL-cholesterol | 0.019 | 0.663 | −0.025 | 0.591 |
| LDL-cholesterol | −0.028 | 0.519 | −0.059 | 0.207 |
Fig. 1prevalence of NAFLD across tertiles of SVR in Chinese type 2 diabetic patients
ORs (95%CI) for NAFLD in type 2 diabetes according to SVR tertiles
| Univariate | Model1 | Model2 | ||||
|---|---|---|---|---|---|---|
| OR | P | OR | P | OR | P | |
| Men | ||||||
| Q1 | 4.27(2.12–8.61) | 0.000 | 4.79(2.17–10.56) | 0.000 | 2.83(0.55–8.43) | 0.213 |
| Q2 | 2.26(1.12–4.55) | 0.022 | 2.38(1.16–4.88) | 0.018 | 1.43(0.40–5.17) | 0.581 |
| Q3 | 1(reference) | – | 1 | – | 1 | – |
| women | ||||||
| Q1 | 3.43(1.70–6.91) | 0.001 | 4.41(1.99–9.74) | 0.001 | 3.43(1.41–8.74) | 0.020 |
| Q2 | 1.98(0.98–3.97) | 0.056 | 2.41(1.13–5.13) | 0.023 | 2.31(1.01–5.63) | 0.046 |
| Q3 | 1 | – | 1 | – | 1 | – |
Model1: adjusted for age
Model2: further adjusted for duration diabetes, BMI, waist, SBP, DBP, HbA1c, smoker, alcohol, ALT, AST, TC, TG, HDL-C, LDL-C, and medication history for diabetes and dyslipidemia
Fig. 2a ROC analysis of SVR to NAFLD among men patients. b ROC analysis of SVR to NAFLD among women patients